相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CAR-NK for tumor immunotherapy: Clinical transformation and future prospects
Wenxiu Wang et al.
CANCER LETTERS (2020)
Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma
Dashnamoorthy Ravi et al.
LEUKEMIA (2020)
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia
C. Quintarelli et al.
LEUKEMIA (2020)
CAR T and CAR NK cells in multiple myeloma: Expanding the targets
Urvi A. Shah et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations
Aiyun Jin et al.
BONE MARROW TRANSPLANTATION (2020)
Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells
Tatsuki Ueda et al.
CANCER SCIENCE (2020)
TIGIT as an emerging immune checkpoint
H. Harjunpaa et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells
Genki Okumura et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
Julia Hambach et al.
CELLS (2020)
Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies
Junji Tanaka et al.
BLOOD REVIEWS (2020)
Cord Blood CAR-NK Cells: Favorable Initial Efficacy and Toxicity but Durability of Clinical Responses Not Yet Clear
Anastasios Karadimitris
CANCER CELL (2020)
High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia
Stephan Mueller et al.
FRONTIERS IN IMMUNOLOGY (2020)
Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D
Ece Canan Sayitoglu et al.
FRONTIERS IN IMMUNOLOGY (2020)
NK Cell-Based Immune Checkpoint Inhibition
Muhammad Khan et al.
FRONTIERS IN IMMUNOLOGY (2020)
CAR Natural Killer Cell Therapy Safe and Effective in First Trial
Jennifer Abbasi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells
Xiaomei Wang et al.
BLOOD ADVANCES (2020)
A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis
Chengui Lu et al.
MOLECULAR IMMUNOLOGY (2020)
Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth
Sarah Oelsner et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Takahiro Kamiya et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
Yingxi Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
A safe and potent anti-CD19 CAR T cell therapy
Zhitao Ying et al.
NATURE MEDICINE (2019)
Managing the toxicities of CAR T-cell therapy
Sattva S. Neelapu
HEMATOLOGICAL ONCOLOGY (2019)
Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges
Luyao Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Jennifer N. Brudno et al.
BLOOD REVIEWS (2019)
Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Chiara F. Magnani et al.
BLOOD (2019)
Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells
Michelle L. Saetersmoen et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches
Mylinh T. Duong et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells
L. Herrera et al.
SCIENTIFIC REPORTS (2019)
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
E. Liu et al.
LEUKEMIA (2018)
Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell
Chu Lin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation
Sarah Cooley et al.
BLOOD (2018)
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li et al.
CELL STEM CELL (2018)
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia
Chiara F. Magnani et al.
HUMAN GENE THERAPY (2018)
A Rapamycin-Activated Caspase 9-Based Suicide Gene
Maria Stavrou et al.
MOLECULAR THERAPY (2018)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Rohtesh S. Mehta et al.
FRONTIERS IN IMMUNOLOGY (2018)
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
K. H. Chen et al.
LEUKEMIA (2017)
Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani et al.
MOLECULAR THERAPY (2017)
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
Kevin G. Pinz et al.
ONCOTARGET (2017)
Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice
Yaya Chu et al.
ONCOIMMUNOLOGY (2017)
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma
Sarah Oelsner et al.
CYTOTHERAPY (2017)
Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer
David L. Hermanson et al.
STEM CELLS (2016)
Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival
Sarah Oelsner et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies
Annette Romanski et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform
Chiara F. Magnani et al.
ONCOTARGET (2016)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
J. Chu et al.
LEUKEMIA (2014)
Improving the safety of cell therapy products by suicide gene transfer
Benjamin S. Jones et al.
Frontiers in Pharmacology (2014)
A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
Yu-Hsiang Chang et al.
CANCER RESEARCH (2013)
Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
Laurent Boissel et al.
ONCOIMMUNOLOGY (2013)
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
V. Hoyos et al.
LEUKEMIA (2010)
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells
Tina Mueller et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells
Juan Vera et al.
BLOOD (2006)
分享论文
